Argenx
ARGX
#538
Rank
NZ$63.61 B
Marketcap
$1,042
Share price
1.01%
Change (1 day)
65.11%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2024 (TTM): NZ$0.14 Billion

According to Argenx 's latest financial reports the company's current earnings are NZ$2.19 Billion. , an increase over its 2023 earnings that were of -NZ$0.52 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2024

Annual earnings

Year Earnings Change
2024 NZ$0.14 B-127.97%
2023 -NZ$0.52 Billion-58.25%
2022 -NZ$1.23 Billion
2019 -NZ$0.34 Billion124.95%
2018 -NZ$0.15 Billion132.04%
2017 -NZ$63.99 Million54.86%
2016 -NZ$41.32 Million33%
2015 -NZ$31.07 Million13.63%
2014 -NZ$27.34 Million46.25%
2013 -NZ$18.7 Million